• Holdings Patent
  2010: 4,584

  Holdings of Biological Material for Patent over lastdecade

• 

China General Microbiological Culture Collection Center (CGMCC) established in 1979, is a non-profit organization financed by the Chinese Academy of Sciences. It has been designated as a depository organization in China for patent purpose by Patent Bureau of China since 1985, and has served as an International Depository Authority (IDA) under the regulations of the Budapest Treaty since 1995. At present, CGMCC hosts 15215 items of biological materials for patent purpose, which is the second highest number of patent deposits among the 45 IDAs under Budapest Treaty. Including the microbial strains deposited in public collection of CGMCC, its collections currently comprise more than 61000 microorganisms which are composed of 2111 genera and 6183 species. And all these biological materials accepted in the CGMCC are subject to extensive quality control since CGMCC passed the audit conducted by China Quality Certification Center and acquired certificate for compliance with the standard ISO 9001 in 2010.

• 

  The identification of clinical-grade human embryonic stem cells and their derivatives

The Beijing Stem Cell Bank has established more than 500 clinical-grade cell lines, including more than 300 clinical-grade human embryonic stem cell lines, which can basically match the population of more than 70% HLA-A/B of the Han population. These cell lines conform to the criteria for clinical-grade stem cells made by international organizations, such as the ISSCR (International Society for Stem Cell Research) and ISCF (International Stem Cell Forum). In April 11, 2017, two Chinese stem cell clinical research projects — "neural precursor cells derived from human embryonic stem cells for the treatment of Parkinson's disease" and "retinal pigment epithelial cells derived from human embryonic stem cells for the treatment of dry age-related macular degeneration" were launched in China, which was recorded by the NHC (National Health Commission of the People’s Republic of China) and CFDA (China Food and Drug Administration). These have brought dawn to treat Parkinson's disease and age-related macular degeneration. It is also great significance to open up a new chapter for curing many refractory diseases.

• 

  A. Propagation lab, B. Outdoor tubular photo-bioreactors, C. Harvest workshops, D. Dry algal powder

China has been leading microalgae industry over 20 years in the world, with the steady increase in the global and domestic market. While Spirulina, a blue-green alga, remains as a major product in the market, Haematococcus, a green alga, is becoming a new focus in microalgal industry due to increasing demanding for its pigment such as astathanthin. Over the past 5 years, FACHB-Collection has been actively engaged in the selection and breeding of Haematococcus, obtaining several strains featured in fast growth and high content of astathanthin; Meanwhile, a set of protocols suitable for mass culture are developed and applied. Taking advantage of large collection of strains, a set of techniques and protocols for scale-up cultivation, we helped establishment of one of Haematococcus companies, named Qujing Bohao in Yunnan province. The administration and demonstration of the techniques and protocols in the large-scale production of Haematococcus has been contributing to the fast and healthy development in microalgal industry.

The Microorganisms & Viruses Culture Collection Center (MVCCC), Wuhan Institute of Virology (WIV), Chinese Academy of Sciences (CAS), has been officially authorized as one of the “National Culture Collection Center” by the National Health Commission of the People’s Republic of China in April 2018. Based on Wuhan's BSL-4 laboratory platform, the center is equipped and qualified to preserve the microorganisms and viruses of all biosafety grades, and will play significant roles in the fields of national security, life science research, public health and virology research.

For supporting the country's strategic demands, MVCCC responded promptly to the epidemic prevention of the recent outbreak of Zika virus (ZIKV), and success in isolation of a new strain of ZIKV and import of 27 strains from France, the United States, etc. MVCCC has been assigned as one of the distribution centers in China by the European Virus Archive goes global (EVAg) project. To date, more than 10 domestic research institutions have applied and obtained the ZIKV strains and related antibodies of up to 35 items from MVCCC. Meanwhile, MVCCC performed the phylogenetic analysis of ZIKV, which firstly discovered that the global ZIKV strains can be divided into three genotypes and revealed the geographic origins of ZIKV outbreaks and epidemics. These findings provide insights into further epidemiological studies of ZIKV, which is important for the prevention and control of ZIKV epidemics.